Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database.

Calapai, Fabrizio; Ammendolia, Ilaria; Cardia, Luigi; Currò, Mariaconcetta; Calapai, Gioacchino; Esposito, Emanuela; Mannucci, Carmen

Calapai, Fabrizio; Ammendolia, Ilaria; Cardia, Luigi; Currò, Mariaconcetta; Calapai, Gioacchino; Esposito, Emanuela; Mannucci, Carmen.

Afiliación

Calapai F; Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Ammendolia I; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98125 Messina, Italy.
Cardia L; Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Currò M; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98125 Messina, Italy.
Calapai G; Department of Human Pathology of Adult and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Esposito E; Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Mannucci C; Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy.

Pharmaceutics ; 15(7)2023 Jul 11.

Article en En | MEDLINE | ID: mdl-37514118

Palabras clave

adverse reactions; anti-IL-23; gender; pharmacovigilance; psoriasis; risankizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google